Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »
5/24 von 412    DIMDI: MEDLINE (ME66) © NLM
ND: ME16942821
PMID: 16942821
CED: 20061124
DCO: 20070327
Autoren: Hathcock JN; Shao A
Titel: Risk assessment for glucosamine and chondroitin sulfate.
Quelle: Regulatory toxicology and pharmacology : RTP; VOL: 47 (1); p. 78-83 /200702/
PM: Print-Electronic
EPD: 20060830
SU: IM
Sprache: English
CY: United States
JID: 8214983
ISSN: 0273-2300
CO: RTOPDW
Institution: Council for Responsible Nutrition, Washington, DC 20036-5114, USA. jhathcock@crnusa.org
DT: Journal Article; Review
RN: 49
Schlagwörter
CT: ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; CHONDROITIN SULFATES/*toxicity; DIETARY SUPPLEMENTS/*toxicity; GLUCOSAMINE/*toxicity; HUMANS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RISK ASSESSMENT
CTG: APPLIKATION, ORALE; TIER; ZELLEN, KULTIVIERTE; CHONDROITINSULFATE/*Toxizität; NAHRUNGSERGÄNZUNGSMITTEL/*Toxizität; GLUCOSAMIN/*Toxizität; MENSCH; MAXIMALE KONZENTRATION OHNE SCHÄDLICHE WIRKUNG; RISIKOABSCHÄTZUNG
TE: Glucosamine/3416-24-8; Chondroitin Sulfates/9007-28-7
CR: 3416-24-8; 9007-28-7
AB: Glucosamine and chondroitin sulfate are two popular dietary ingredients present in dietary supplements intended to support joint health. A large body of human and animal research suggests that oral intakes of these ingredients, either alone or in combination, reduces joint pain and improves mobility in persons with osteoarthritis. The increased awareness and use of these ingredients in dietary supplements warrant a comprehensive review of their safety. Systematic evaluation of the research designs and data do not provide a basis for risk assessment and the usual safe upper level of intake (UL) derived from it unless the newer methods described as the observed safe level (OSL) or highest observed intake (HOI) are utilized. The OSL risk assessment method indicates that the evidence strongly supports safety at intakes up to 2000 mg/d for glucosamine, and 1200 mg/d for chondroitin sulfate, and these levels are identified as the respective OSL. These values represent the highest levels tested in human clinical trials. The complete absence of adverse effects at these levels supports a confident conclusion of their long-term safety.
» Volltext »

» Fenster schließen »